Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 14Uveal Melanoma 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Basal Cell 2Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Tertiary Lymphoid Structures 1Spinocerebellar Degenerations 1Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Microsatellite Instability 1Male Urogenital Diseases 1Locally Advanced Melanoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Gastroesophageal Cancer 1

Interventions

Nivolumab 3pembrolizumab 2durvalumab 2tremelimumab 1relatlimab 1lentiviral minigene vaccine of COVID-19 coronavirus 1fludarabine phosphate 1fludarabine 1bintrafusp alfa protein, human 1avelumab 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Specimen Handling 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Injections 1Immunoglobulin G 1High-Throughput Nucleotide Sequencing 1Educational Status 1Drug Therapy 1Disulfides 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Microsatellite Instability × relatlimab × Clear all
NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡